From Bloomberg:
"As far as these deals have gone recently, this one is relatively cheap. Bristol-Myers Squibb Co. paid substantially more last week for limited access to a Nektar Therapeutics Inc. medicine with more heavily hyped early trial data."
https://www.bloomberg.com/gadfly/ar...iralytics-deal-just-doubling-down-on-keytruda